ArticleScientific reports2025
Comprehensive analysis of single-cell and bulk RNA sequencing uncover tumor microenvironment diversity in invasive Retinoblastoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In this study, we analyzed publicly available scRNA-seq data from primary tumor tissues of 10 Retinoblastoma (RB) patients to explore tumor microenvironment (TME) heterogeneity. Our findings revealed distinct subpopulations of cone precursor (CP) cells, with higher proportions in invasive RB. Differential gene expression and pathway analysis highlighted functional diversity among CP subpopulations, with CP4 showing elevated TGF-β signaling in invasive RB. Cell-cell interaction analysis further identified rewiring of communication networks, with increased fibroblast-CP interactions in invasive tumors. Bulk RNA-seq identified two molecular subtypes, with subtype 1 showing an immunosuppressive TME. Finally, DOK7 was identified as a key gene associated with invasion, with functional assays confirming its role in promoting tumor progression. These results provide valuable insights into RB progression and potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.